APOE ε4 is the strongest common genetic risk factor for cardiovascular disease and Alzheimer's disease. It impairs LDL clearance and promotes inflammatory lipid metabolism — APOE ε4 carriers have significantly elevated LDL and cardiovascular event risk at standard cholesterol levels. Among the most actionable findings in consumer genomics.
PCSK9 encodes a protein that degrades LDL receptors on liver cells — reducing LDL clearance from circulation. Gain-of-function variants elevate LDL levels substantially and are associated with familial hypercholesterolemia-like phenotypes. Loss-of-function variants are naturally protective — the genetic basis for the PCSK9 inhibitor drug class.
ACE (angiotensin-converting enzyme) and AGT (angiotensinogen) variants are key determinants of blood pressure regulation and salt sensitivity. The ACE D allele associates with elevated blood pressure and cardiovascular risk — and with differential response to ACE inhibitor therapy. A central variant for dietary sodium and exercise protocol personalization.
Cardiovascular disease is an inflammatory condition as much as a metabolic one. IL6 and CRP variants determine baseline vascular inflammatory tone — affecting atherosclerotic plaque development, endothelial function, and cardiovascular event risk independent of lipid levels. A genetic basis for anti-inflammatory lifestyle and supplement protocols.
Elevated homocysteine is an independent cardiovascular risk factor. MTHFR C677T reduces homocysteine methylation capacity — elevating plasma homocysteine and increasing vascular endothelial damage risk. The cardiovascular implication of MTHFR extends beyond neurological effects and is directly addressable through folate and B12 supplementation.
Platelet receptor variants affect aggregation response and thrombosis risk — particularly relevant to antiplatelet medication selection, exercise recommendations for individuals with elevated cardiovascular risk, and dietary interventions targeting omega-3s and aspirin-like compounds.
APOE, PCSK9, LDLR, and PCSK9-adjacent variant profiling — structured as a cardiovascular lipid risk assessment. Each finding graded by evidence level and linked to dietary, lifestyle, and monitoring recommendations for that specific genetic risk.
ACE, AGT, and ADD1 variants informing salt sensitivity, response to aerobic exercise for blood pressure management, and dietary intervention priorities. The genetic context that makes blood pressure management protocols specific rather than generic.
IL6, CRP, and TNF variant profiles providing a genetic vascular inflammation assessment. Actionable: anti-inflammatory dietary patterns, omega-3 dose guidance, and exercise type recommendations based on the specific inflammatory genetic risk.
Cardiovascular genetics connected to nutrition, supplement, and lifestyle domains — a coherent protocol that addresses the specific combination of lipid, blood pressure, and inflammatory variants rather than single-variant recommendations that miss the compound picture.
Whether you're building a longevity platform, a clinical tool, or a preventive health product — let's discuss how cardiovascular genomic intelligence integrates into your product and user experience.